

CLAIMS

What is claimed is:

1. Use of an antibody or an antigen-binding fragment thereof that specifically binds interleukin-4 receptor (IL-4R) in the manufacture of a medicament for treating asthma in a subject aged 6 years old and older,

wherein the subject has moderate-to-severe asthma with type 2 inflammation characterized by an eosinophilic phenotype and/or elevated fraction of exhaled nitric oxide (FeNO), or

wherein the subject has oral corticosteroid-dependent asthma,

wherein the antibody or an antigen-binding fragment thereof is to be administered to the subject,

wherein the antibody or antigen-binding fragment thereof comprises three heavy chain CDR sequences comprising SEQ ID NOs: 3, 4, and 5, respectively, and three light chain CDR sequences comprising SEQ ID NOs: 6, 7, and 8, respectively.

2. The use of claim 1, wherein the antibody or antigen-binding fragment thereof is to be administered to the subject as an initial dose followed by one or more secondary doses.

3. The use of claim 2, wherein the initial dose is about 100 mg and each secondary dose is about 100 mg.

4. The use of claim 3, wherein the subject weighs 15 kg to less than 30 kg.

5. The use of claim 2, wherein the initial dose is about 200 mg and each secondary dose is about 200 mg.

6. The use of claim 5, wherein the subject weighs equal to or greater than 30 kg.

7. The use of claim 3 or 5, wherein the antibody or antigen-binding fragment thereof is to be administered to the subject once every other week (q2w).

8. The use of claim 2, wherein the initial dose is about 300 mg and each secondary dose is about 300 mg.
9. The use of claim 5, wherein the subject weighs 15 kg to less than 30 kg.
10. The use of claim 9, wherein the antibody or antigen-binding fragment thereof is to be administered to the subject once every four weeks (q4w).
11. The use of any one of claims 1 to 10, wherein the subject is less than 12 years old.
12. The use of any one of claims 1-11, wherein the FeNO level is ≥ 20 ppb or ≥ 25 ppb.
13. Use of an antibody or an antigen-binding fragment thereof that specifically binds interleukin-4 receptor (IL-4R) in the manufacture of a medicament for treating asthma in a subject aged 6 years old to less than 12 years old,
wherein one or more doses of the antibody or antigen-binding fragment thereof is to be administered to the subject,
wherein the antibody or antigen-binding fragment thereof comprises three heavy chain CDR sequences comprising SEQ ID NOs: 3, 4, and 5, respectively, and three light chain CDR sequences comprising SEQ ID NOs: 6, 7, and 8, respectively, and
wherein the antibody or antigen-binding fragment thereof is to be administered to the subject as an initial dose followed by one or more secondary doses.
14. The use of claim 13, wherein each secondary dose is to be administered 1 to 4 weeks after the immediately preceding dose, and wherein:
 - (i) for a subject having a body weight of ≤ 30 kg, the initial dose of the antibody or antigen-binding fragment thereof is 100 mg and each secondary dose is 100 mg; or
 - (ii) for a subject having a body weight of >30 kg, the initial dose of the antibody or antigen-binding fragment thereof is 200 mg and each secondary dose is 200 mg.

15. The use of claim 13, wherein the subject has asthma with a Type 2 inflammatory phenotype that includes one or both of a baseline blood eosinophil count of greater than or equal to 150 cells/ μ L and a baseline FeNO of greater than or equal to 20 ppb.
16. The use of claim 13, wherein maintenance doses of the antibody or antigen-binding fragment thereof are to be administered for at least 24 weeks.
17. The use of any of the preceding claims, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) sequence of SEQ ID NO: 2.
18. The use of any of the preceding claims, wherein the antibody is dupilumab.
19. The use of any of the preceding claims, wherein the antibody or antigen-binding fragment thereof is to be administered using an autoinjector, a needle and syringe, or a pen.
20. The use of any of the preceding claims, wherein the antibody or antigen-binding fragment thereof is to be administered subcutaneously.